Bacterium Actively Drives CRC Tumor Growth
|
By LabMedica International staff writers Posted on 27 Jul 2017 |

Image: The gut contains trillions of microorganisms, but new research finds one bacterium that drives the growth of colorectal cancer cells (Photo courtesy of MNT).
Colorectal cancer (CRC) is a leading cause of cancer-related death. The recognition that microbial agents can contribute to the development of CRC raises hope for improving CRC diagnosis and treatment by incorporating both microbial and patient characteristics into clinical strategies.
It has been known for some time that people infected with the Streptococcus gallolyticus subspecies gallolyticus (Sgg) are more likely to have colorectal cancer (CRC), and is the second most common cause of cancer in women. However, it was unknown whether Sgg actively promotes CRC or whether it simply grows comfortably in the environment provided by CRC tumor cells.
Scientists at Texas A&M Health Science Center (Houston, TX, USA) and colleagues performed several studies using cultured human colorectal cells, mice with CRC, and tissue from human tumors. They used various techniques including using cultured bacterial cell lines, human colon cancer cell lines, cell proliferation assays, adherence and internalization assays, Western blot assays. They also performed quantitative reverse transcription polymerase chain reaction (RT-qPCR) to compare relative expression of cyclin D1 and cytokines in a Viia 7 Real Time PCR System. Flow cytometry analysis of samples was done using a LSRII flow cytometer.
The investigators demonstrated that Sgg promotes human colon cancer cell proliferation in a manner that depends on cell context, bacterial growth phase and direct contact between bacteria and colon cancer cells. In addition, they observed increased level of β-catenin, c-Myc and proliferating cell nuclear antigen (PCNA) in colon cancer cells following incubation with Sgg. The team tested tumor samples from people with colon cancer, they found 74% had Sgg bacteria in them, and 26% had very high levels of it. They also showed that Sgg is present in the majority of CRC patients and is preferentially associated with tumor compared to normal tissues obtained from CRC patients.
The authors concluded that overall, their findings strongly suggest that Sgg plays an active role in CRC development in humans. In the future, the precise mechanisms of its tumor-promoting activity could potentially be exploited to develop new strategies to diagnose, prevent, and treat CRC. The study was published on July 13, 2017, in the journal Public Library of Science Pathogens.
Related Links:
Texas A&M Health Science Center
It has been known for some time that people infected with the Streptococcus gallolyticus subspecies gallolyticus (Sgg) are more likely to have colorectal cancer (CRC), and is the second most common cause of cancer in women. However, it was unknown whether Sgg actively promotes CRC or whether it simply grows comfortably in the environment provided by CRC tumor cells.
Scientists at Texas A&M Health Science Center (Houston, TX, USA) and colleagues performed several studies using cultured human colorectal cells, mice with CRC, and tissue from human tumors. They used various techniques including using cultured bacterial cell lines, human colon cancer cell lines, cell proliferation assays, adherence and internalization assays, Western blot assays. They also performed quantitative reverse transcription polymerase chain reaction (RT-qPCR) to compare relative expression of cyclin D1 and cytokines in a Viia 7 Real Time PCR System. Flow cytometry analysis of samples was done using a LSRII flow cytometer.
The investigators demonstrated that Sgg promotes human colon cancer cell proliferation in a manner that depends on cell context, bacterial growth phase and direct contact between bacteria and colon cancer cells. In addition, they observed increased level of β-catenin, c-Myc and proliferating cell nuclear antigen (PCNA) in colon cancer cells following incubation with Sgg. The team tested tumor samples from people with colon cancer, they found 74% had Sgg bacteria in them, and 26% had very high levels of it. They also showed that Sgg is present in the majority of CRC patients and is preferentially associated with tumor compared to normal tissues obtained from CRC patients.
The authors concluded that overall, their findings strongly suggest that Sgg plays an active role in CRC development in humans. In the future, the precise mechanisms of its tumor-promoting activity could potentially be exploited to develop new strategies to diagnose, prevent, and treat CRC. The study was published on July 13, 2017, in the journal Public Library of Science Pathogens.
Related Links:
Texas A&M Health Science Center
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







